Ibrutinib-naïve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance
Copyright policy )Ibrutinib-naïve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance
To the editor: The Bruton tyrosine kinase (BTK) inhibitor ibrutinib blocks B-cell receptor signaling via covalent binding of the BTK C481 residue.[1][1] Although ibrutinib induces durable remissions in relapsed/refractory chronic lymphocytic leukemia (CLL), a fraction of patients treated with this
Adenine, DNA Mutational Analysis, 610, Protein-Tyrosine Kinases, Leukemia, Lymphocytic, Chronic, B-Cell, Polymerase Chain Reaction, Cohort Studies, Pyrimidines, Piperidines, Drug Resistance, Neoplasm, 616, Mutation, Agammaglobulinaemia Tyrosine Kinase, Humans, Pyrazoles, Alleles
Adenine, DNA Mutational Analysis, 610, Protein-Tyrosine Kinases, Leukemia, Lymphocytic, Chronic, B-Cell, Polymerase Chain Reaction, Cohort Studies, Pyrimidines, Piperidines, Drug Resistance, Neoplasm, 616, Mutation, Agammaglobulinaemia Tyrosine Kinase, Humans, Pyrazoles, Alleles
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).27 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!